Tokushima University / Educator and Researcher Directory --- Hara, Keijiro

Search:

Tokushima University ⟩ University Hospital ⟩ Central Clinical Facilities ⟩ Regioal Neurosurgery ⟩
Tokushima University ⟩ University Hospital ⟩ Clinical Division ⟩ Department of Neurosurgery, Psychiatry and Anesthesiology ⟩ Neurosurgery ⟩

(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Mai Azumi, Yoshifumi Mizobuchi, Nobuto Nakanishi, Kohhei Nakajima, Keijiro Hara, Toshitaka Fujihara, Manabu Ishihara, Jun Oto and Yasushi Takagi : Value of the Acute Physiology and Chronic Health Evaluation II (APACHE II) score in predicting hospital mortality for postoperative brain tumor patients in intensive care units in Japan: A retrospective case-control study, Clinical Neurology and Neurosurgery, Vol.244(2024), No.108435, 108435, 2024. (Summary) Acute Physiology and Chronic Health Evaluation II (APACHE II) is based on the data of intensive care unit (ICU) patients and often correlates with disease severity and prognosis. However, no prognostic predictors exist based on ICU admission data for patients with brain tumors, and no studies have reported an association between APACHE II and prognosis in patients with brain tumors. The Japanese Intensive Care Patients Database (JIPAD) was established to improve the quality of care delivered in intensive care medicine in Japan. We used JIPAD to examine factors associated with in-hospital mortality based on available data of postoperative patients with brain tumors admitted to the ICU. Patients aged ≥16 years enrolled in JIPAD between April 2015 and March 2018 after surgical brain tumor resection or biopsy of brain tumors. We examined factors related to outcomes at discharge based on blood tests and medical procedures performed during ICU admission, tumor type, and APACHE II score. Among the 1454 patients (male:female ratio: 1:1.1, mean age: 62 years) in the study, 32 (2.2 %) died during hospital stay. In multivariate analysis, male sex (odds ratio [OR] 2.70, [95 % confidence interval, CI 1.22-6.00]), malignant tumor (OR 2.51 [95 % CI 1.13-5.55]), and APACHE II score ≥15 (OR 2.51 [95 % CI 3.08-14.3]) were significantly associated with in-hospital mortality. By picking up cases with a high risk of in-hospital death at an early stage, it is possible to improve methods of treatment and support for the patient's family. (Keyword) Humans / Male / Female / Middle Aged / Hospital Mortality / APACHE / Japan / Brain Neoplasms / Aged / Intensive Care Units / Retrospective Studies / Case-Control Studies / Adult / Prognosis / Aged, 80 and over / Predictive Value of Tests (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clineuro.2024.108435 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38996799 ● Summary page in Scopus @ Elsevier: 2-s2.0-85198060266 (DOI: 10.1016/j.clineuro.2024.108435, PubMed: 38996799, Elsevier: Scopus)
2.	Shingen Nakamura, Keijiro Hara, Tomoko Kobayashi, Ryohei Sumitani, Masahiro Oura, Yusaku Maeda, Kimiko Sogabe, Hikaru Yagi, Mamiko Takahashi, Shiroh Fujii, Takeshi Harada, Yoshimi Bando, Masahiro Abe and Hirokazu Miki : Tl uptake and retention mimicking malignant lymphoma in a patient with human immunodeficiency virus infection., Parasitology International, Vol.101, 102895, 2024. (Summary) Various opportunistic infections develop during immunodeficiency due to human immunodeficiency virus (HIV) infection. The treatment options for malignant lymphoma (ML) and toxoplasmic encephalitis (TE) are completely different; therefore, their discrimination is critical. A 25-year-old female of foreign nationality had been experiencing headaches for several weeks and suddenly developed convulsions. Brain computed tomography revealed multiple intracranial lesions; therefore, the patient was referred to the neurosurgery department. Brain magnetic resonance imaging (MRI) revealed multiple masses with surrounding edema, accompanied by enhanced contrast. The largest mass (2 cm) in the left occipital lobe exhibited ringed contrast enhancement. Her blood test results showed a CD4 count of 40/μL, positive HIV Ag/Ab, HIV-RNA level of 56 × 10 copies/mL, positive anti-Toxoplasma IgG (63 IU/mL), and negative anti-Toxoplasma IgM. Tl- single photon emission computed tomography (Tl-SPECT) revealed abnormal accumulation only in the tumor in the left occipital lobe (early T/N ratio, 3.034; delayed T/N ratio, 2.738; retention index, 0.9), which was suspected to be a ML. Both tumors, with or without high accumulation of Tl, were subjected to craniotomy biopsy. Pathological examination revealed infiltration of small lymphocytes with a necrotic background. The patient was diagnosed with TE based on a positive result of a tissue polymerase chain reaction test for Toxoplasma gondii. Two weeks after sulfamethoxazole and trimethoprim combination therapy, MRI imaging showed dramatic improvement in multiple brain tumors. This case is atypical because ML was ruled out despite high Tl-SPECT uptake and retention. Careful diagnosis through pathological examination and DNA testing is important. (Keyword) Humans / Female / Adult / Toxoplasmosis, Cerebral / Lymphoma / HIV Infections / Magnetic Resonance Imaging / Diagnosis, Differential / Tomography, Emission-Computed, Single-Photon / Toxoplasma (Tokushima University Institutional Repository) ● Metadata: 119634 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.parint.2024.102895 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38614255 ● Search Scopus @ Elsevier (PMID): 38614255 ● Search Scopus @ Elsevier (DOI): 10.1016/j.parint.2024.102895 (Tokushima University Institutional Repository: 119634, DOI: 10.1016/j.parint.2024.102895, PubMed: 38614255)
3.	Hiroshi Kagusa, Yamaguchi Izumi, Shono Kenji, Mizobuchi Yoshifumi, Shikata Eiji, Taku Matsuda, Takeshi Miyamoto, Keijiro Hara, Kitazato T Keiko, Yoshihiro Uto, Kanematsu Yasuhisa and Yasushi Takagi : Differences in amyloid-β and tau/p-tau deposition in blood-injected mouse brains using micro-syringe to mimic traumatic brain microhemorrhages, Journal of Chemical Neuroanatomy, Vol.130, 102258, 2023. (Summary) Cerebral microbleeds (CMBs) due to traumatic brain injuries (TBI) have been shown to lead to cognitive decline and impairment. CMBs caused by TBI may be associated with pathophysiological mechanisms involving inflammation and the accumulation of amyloid-β (Aβ), tau, and phosphorylated tau (p-tau), contributing to cognitive abnormalities. However, their relationships remain unclear. To test our hypothesis that Aβ, tau, and p-tau are accumulated and regulated separately in mice with injuries imitating CMBs from TBI, we studied. Seven-week-old C57BL/6 male mice were injected with 15 μL of heparinized autologous blood or saline by micro-syringe into the front lobe. Expression profiles and regulation of Aβ, tau, and p-tau were assessed immunohistochemically over time. On day 7 after blood injection, Iba-1 and S100B cells in damaged cortex adjacent to the injection site were higher than saline injection group and non-injected sham. On days 3-14, Aβ deposition were gradually increased but normalized by day 28. In contrast, tau/p-tau deposition gradually increased during days 14-28 and dispersed along the corticomedullary junction adjacent to hem deposits, indicating different expression profiles from Aβ. Deposits of Aβ, but not tau/p-tau, were phagocytosed by CD163 macrophages increased by Gc-protein macrophage-activating factor during days 7-28, suggesting different mechanisms of deposition and regulation between Aβ and tau/p-tau. Deposition and regulation differ between Aβ and tau/p-tau in mice with injuries mimicking CMBs from TBI. Further clarification of relationships between the pathologies of cognitive impairment and their neurodegenerative consequences is needed. (Keyword) Amyloid-β / Cognitive impairment / Tauopathy / Traumatic cerebral microbleed (Tokushima University Institutional Repository) ● Metadata: 119582 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jchemneu.2023.102258 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36925083 ● Search Scopus @ Elsevier (PMID): 36925083 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jchemneu.2023.102258 (Tokushima University Institutional Repository: 119582, DOI: 10.1016/j.jchemneu.2023.102258, PubMed: 36925083)
4.	Kohei Muto, Ryosuke Miyamoto, Yuka Terasawa, Yoshimitsu Shimatani, Keijiro Hara, Takumi Kakimoto, Tatsuya Fukumoto, Yusuke Osaki, Koji Fujita, Masafumi Harada, Hisanori Uehara, Yasushi Takagi and Yuishin Izumi : A novel COL4A1 variant associated with recurrent epistaxis and glioblastoma, Human Genome Variation, Vol.8, No.1, 18, 2021. (Tokushima University Institutional Repository) ● Metadata: 116530 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41439-021-00150-0 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85105944271 (Tokushima University Institutional Repository: 116530, DOI: 10.1038/s41439-021-00150-0, Elsevier: Scopus)
5.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Teruyoshi Kageji, Kazuhito Matsuzaki, KT Kitazato, Ryotaro Otsuka, Keijiro Hara, Hideo Mure, Toshiyuki Okazaki, Kazuyuki Kuwayama, Shinji Nagahiro and Yasushi Takagi : Down-regulation of MDR1 by Ad-DKK3 via Akt/NFB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model, Journal of Neuro-Oncology, Vol.139, No.2, 323-332, 2018. (Summary) Glioblastoma multiforme (GBM) is the most malignant of brain tumors. Acquired drug resistance is a major obstacle for successful treatment. Earlier studies reported that expression of the multiple drug resistance gene (MDR1) is regulated by YB-1 or NFκB via the JNK/c-Jun or Akt pathway. Over-expression of the Dickkopf (DKK) family member DKK3 by an adenovirus vector carrying DKK3 (Ad-DKK3) exerted anti-tumor effects and led to the activation of the JNK/c-Jun pathway. We investigated whether Ad-DKK3 augments the anti-tumor effect of temozolomide (TMZ) via the regulation of MDR1. GBM cells (U87MG and U251MG), primary TGB105 cells, and mice xenografted with U87MG cells were treated with Ad-DKK3 or TMZ alone or in combination. Ad-DKK3 augmentation of the anti-tumor effects of TMZ was associated with reduced MDR1 expression in both in vivo and in vitro studies. The survival of Ad-DKK3-treated U87MG cells was inhibited and the expression of MDR1 was reduced. This was associated with the inhibition of Akt/NFκB but not of YB-1 via the JNK/c-Jun- or Akt pathway. Our results suggest that Ad-DKK3 regulates the expression of MDR1 via Akt/NFκB pathways and that it augments the anti-tumor effects of TMZ in GBM cells. (Tokushima University Institutional Repository) ● Metadata: 112895 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11060-018-2894-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29779087 ● Summary page in Scopus @ Elsevier: 2-s2.0-85047143200 (Tokushima University Institutional Repository: 112895, DOI: 10.1007/s11060-018-2894-5, PubMed: 29779087, Elsevier: Scopus)
6.	Keijiro Hara, Teruyoshi Kageji, Yoshifumi Mizobuchi, Keiko T. Kitazato, Toshiyuki Okazaki, Toshitaka Fujihara, Kohhei Nakajima, Hideo Mure, Kazuyuki Kuwayama, Tomoyo Hara and Shinji Nagahiro : Blocking of the interaction between Wnt proteins and their co-receptors contributes to the anti-tumor effects of adenovirus-mediated DKK3 in glioblastoma, Cancer Letters, Vol.356, 496-505, 2015. (Summary) The effect of the third member of the Dickkopf family (DKK3) in the Wnt pathway in glioblastoma remains unclear. We first demonstrated the non-specific interaction of Wnt3a and Wnt5a with the receptors LRP6 and ROR2 and the up-regulation of the Wnt pathway in glioblastoma cells. We used an adenovirus vector and found that an increase in DKK3 protein attenuated the expression of Wnt3a, Wnt5a and LRP6, but not of ROR2, and their interaction, thereby affecting both canonical- and non-canonical Wnt downstream cascades. This produced anti-tumor effects in GBM xenograft models. The suppression of Wnt pathways upstream by DKK3 may have promise for the treatment of glioblastoma. (Keyword) Adenoviridae / Animals / apoptosis / Blotting, Western / cell proliferation and differentiation / Flow Cytometry / Genetic Vectors / Glioblastoma / Humans / Immunoenzyme Techniques / Immunoprecipitation / Intercellular Signaling Peptides and Proteins / Low Density Lipoprotein Receptor-Related Protein-6 / male / Mice / Mice, Inbred BALB C / Mice, Nude / Proto-Oncogene Proteins / RNA, Messenger / Real-Time Polymerase Chain Reaction / Receptor Tyrosine Kinase-like Orphan Receptors / Reverse Transcriptase Polymerase Chain Reaction / Tumor Cells, Cultured / Wnt Proteins / Wnt3A Protein / Xenograft Model Antitumor Assays (Tokushima University Institutional Repository) ● Metadata: 106342 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.canlet.2014.09.045 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25301448 ● Summary page in Scopus @ Elsevier: 2-s2.0-84919491383 (Tokushima University Institutional Repository: 106342, DOI: 10.1016/j.canlet.2014.09.045, PubMed: 25301448, Elsevier: Scopus)
7.	Toshiyuki Okazaki, Teruyoshi Kageji, Kazuyuki Kuwamura, Keiko T. Kitazato, Hideo Mure, Keijiro Hara, Ryoma Morigaki, Yoshifumi Mizobuchi, Kazuhito Matsuzaki and Shinji Nagahiro : Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma, Cancer Letters, Vol.323, No.2, 199-207, 2012. (Summary) Interferon-beta (IFN-) is reported to augment anti-tumor effects by temozolomide in glioblastoma via down-regulation of MGMT. Promyelocytic leukemia (PML), a gene induced by IFN-, is a tumor suppressor. Here, we report for the first time that in combination therapy, an IFN--induced increase in endogenous PML contributes to anti-tumor effects in p53 wild- and mutant glioma cells in a xenograft mice model. The increased PML promoted the accumulation of p73, a structural and functional homolog of p53, to fuse the coactivator Yes-associated-protein in the PML nuclear bodies. The adjuvant therapy targeted at PML may be a promising therapeutic strategy for glioblastoma. (Keyword) Apoptosis / Base Sequence / Blotting, Western / Brain Neoplasms / Cell Line, Tumor / DNA Primers / DNA-Binding Proteins / Dacarbazine / Glioblastoma / Humans / Interferon-beta / Nuclear Proteins / Real-Time Polymerase Chain Reaction / Transcription Factors / Tumor Suppressor Proteins / Up-Regulation (Link to Publication Site) ● Publication site (DOI): 10.1016/j.canlet.2012.04.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22542810 ● Search Scopus @ Elsevier (PMID): 22542810 ● Search Scopus @ Elsevier (DOI): 10.1016/j.canlet.2012.04.013 (DOI: 10.1016/j.canlet.2012.04.013, PubMed: 22542810)

Proceeding of International Conference:

1.	Toshitaka Fujihara, Teruyoshi Kageji, Yoshifumi Mizobuchi, Keijiro Hara, Kenji Shouno, Kohhei Nakajima, Hideo Mure, Kazuyuki Kuwayama and Shinji Nagahiro : Down-regulation of MDR1 by DKK3 attenuates chemoresistance to temozolomide, and potentiates its anti-tumor effects, 20th Annual Socientific Meeting and Education Day of the Society for Neuro-Oncology, Nov. 2015.
2.	Yoshifumi Mizobuchi, T Okazaki, Teruyoshi Kageji, Kazuyuki Kuwayama, KT Kitazato, Hideo Mure, Keijiro Hara, Ryoma Morigaki, Kazuhito Matsuzaki, Kohhei Nakajima, T Fujihara and Shinji Nagahiro : A combination of interferon-beta and temozolomide augments anti-tumor effects through p73/YAP-mediated apoptosis by PML in glioblastoma, The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 SNO Scientific Meeting and Education Day, San Francisco, Nov. 2013.
3.	Keijiro Hara, Teruyoshi Kageji, Yoshifumi Mizobuchi, T Okazaki, T Fujihara, Kohhei Nakajima, Hideo Mure, Kazuyuki Kuwayama, T Hara and Shinji Nagahiro : REIC/Dkk-3, one of Dickkopf(Dkk)family members, contributes to the anti-tumor effects in glioblastoma through regulation of both Wnt signal pathways, The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 SNO Scientific Meeting and Education Day, San Francisco, Nov. 2013.
4.	Kohhei Nakajima, Keijiro Hara, Teruyoshi Kageji, Yoshifumi Mizobuchi, KT KItazato, T Fujihara, Kazuyuki Kuwayama, R Otsuka, DK Kung and Shinji Nagahiro : Down-regulation of MDR by Ad-REIC contributes to augment the chemotherapy by temozolomide, The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 SNO Scientific Meeting and Education Day, San Francisco, Nov. 2013.

Proceeding of Domestic Conference:

1.	Taku Matsuda, Keijiro Hara, 鈴木海斗, Kazuhisa Miyake and Yasushi Takagi : A case of cerebrospinal fluid leaks diagnosed by examination of posttraumatic higher brain dysfunction, 日本脳神経外科学会第83回学術総会, Oct. 2024.
2.	Toshitaka Fujihara, Yoshiteru Tada, Mai Azumi, Keijiro Hara, Kohhei Nakajima and Yasushi Takagi : Clinical characteristics and outcome of status epilepticus in patients with brain tumor, 日本脳神経外科学会第83回学術総会, Oct. 2024.
3.	Hiroshi Kagusa, Keijiro Hara, Kohhei Nakajima, 北里慶子, Yasuhisa Kanematsu and Yasushi Takagi : 外傷性脳内微小出血模倣モデルマウスにおける認知機能解析と認知症蛋白の蓄積の検討, 日本脳神経外科学会第83回学術総会, Oct. 2024.
4.	Keijiro Hara, Mai Azumi, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : 開頭摘出術を行った転移性脳腫瘍の術後成績, 日本脳神経外科学会第83回学術総会, Oct. 2024.
5.	Toshitaka Fujihara, Kohhei Nakajima, Mai Azumi, Keijiro Hara and Yasushi Takagi : Tips for temporal lobectomy for malignant brain tumor of temporal lobe, 第29回日本脳腫瘍の外科学会, Oct. 2024.
6.	砂田陽二郎, Mai Azumi, Kohhei Nakajima, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : 成人発症sellar Atypical Teratoid/Rhabdoid Tumorの一例, 第38回中国四国脳腫瘍研究会, Sep. 2024.
7.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Keijiro Hara, Mai Azumi and Yasushi Takagi : Epilepsy and perioperative seizures in surgical cases of supratentorial meningioma, 第57回日本てんかん学会学術集会, Sep. 2024.
8.	Taku Matsuda, Keijiro Hara, Kaito Suzuki, Kazuhisa Miyake and Yasushi Takagi : 外傷後の高次脳機能障害の精査で脳脊髄液漏出症と診断された一例, 23回舞連カンファレンス, Aug. 2024.
9.	Toshitaka Fujihara, Kohhei Nakajima, Keijiro Hara, Mai Azumi, Taku Matsuda, Yoshiteru Tada and Yasushi Takagi : 脳腫瘍生検術におけるStealth Autoguideの初期使用経験, 日本脳神経外科学会第82回学術集会, Oct. 2023.
10.	Kohhei Nakajima, Mai Azumi, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : Sellar atypical teratoid/rhabdoid tumor の1例, 第28回日本脳腫瘍の外科学会, Sep. 2023.
11.	手島奈津美, Mai Azumi, Kohhei Nakajima, Tomohiro Matsuda, Izumi Yamaguchi, Toshitaka Fujihara, Shu Sogabe, Keijiro Hara and Yasushi Takagi : 術後管理に難渋した頭蓋咽頭腫の1例, 第95回日本脳神経外科学会中国四国支部学術集会, Apr. 2023.
12.	Mai Azumi, Toshitaka Fujihara, Keijiro Hara, Kohhei Nakajima, Yoshifumi Mizobuchi and Yasushi Takagi : Examination about the predictors of outcome at discharge in postoperative brain tumor patients admitted to the intensive care units, 日本脳神経外科学会第81回学術総会, Sep. 2022.
13.	Keijiro Hara, Yoshifumi Mizobuchi, Mai Azumi, Shu Sogabe, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : Hyper vascularityを呈した松果体部腫瘍の1例, 第93回日本脳神経外科学会中国四国支部学術集会, Apr. 2022.
14.	Toshitaka Fujihara, Yoshiteru Tada, Yoshifumi Mizobuchi, Kohhei Nakajima, Keijiro Hara, Mai Azumi and Yasushi Takagi : Epilepsy and perioperative seizure management in surgical cases of supratentorial meningioma, 日本脳神経外科学会第80回学術総会, Oct. 2021.
15.	Mai Azumi, Takeshi Miyamoto, Toshitaka Fujihara, Kohhei Nakajima, Keijiro Hara, Yoshifumi Mizobuchi and Yasushi Takagi : 特発性頭蓋内圧亢進様の症状のみで発症した小児脳腫瘍の1例, 第35回中国四国脳腫瘍研究会, Sep. 2021.
16.	Keijiro Hara, Yoshifumi Mizobuchi, Mai Azumi, Kohhei Nakajima and Yasushi Takagi : AIDS関連トキソプラズマ脳症の1例, 第91回(一社)日本脳神経外科学会中国四国支部学術集会, Apr. 2021.
17.	Keijiro Hara, Kyoko Nishi, Junichiro Satomi and Shinji Nagahiro : High flow bypassとdistal occlusionを行った中大脳動脈血栓化紡錘状動脈瘤の一例, 第76回(一社)日本脳神経外科学会中国四国支部学術集会, Dec. 2013.
18.	Keijiro Hara, Yoshifumi Mizobuchi, 北里慶子, 岡﨑敏之, Teruyoshi Kageji, Shinji Nagahiro and 公文裕巳 : 悪性神経膠腫におけるREIC/Dkk-3遺伝子導入によるWnt蛋白制御の意義, 第13回日本分子脳神経外科学会, Sep. 2012.
19.	岡﨑敏之, Kazuhito Matsuzaki, Yoshifumi Mizobuchi, 北里慶子, Teruyoshi Kageji, Keijiro Hara and Shinji Nagahiro : 膠芽腫に対するテモゾロミドとインターフェロンβ併用療法におけるPMLの役割, 徳島脳腫瘍セミナー2010, Feb. 2010.

Et cetera, Workshop:

1.	Mai Azumi, Kohhei Nakajima, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : リツシマブ併用大量療法が奏功した難治性中枢神経原発悪性リンパ腫の1例, 第37回中四国脳腫瘍研究会, Sep. 2023.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

脳内微量出血模倣モデルにおける認知症関連蛋白発現機序の解明と制御 (Project/Area Number: 22K16662 )
Anti-tumor effects and Regulation of Wnt signaling pathway of adenovirus-mediated DKK3 in glioblastoma (Project/Area Number: 25462264 )
Search by Researcher Number (60710340)